P4B (2-phenyl-1-[4-(6-(piperidin-1-yl) pyridazin-3-yl) piperazin-1-yl] butan-1-one) is a novel cellulose biosynthesis inhibitor (CBI) discovered in a screen for molecules to identify inhibitors of Arabidopsis (Arabidopsis thaliana) seedling growth. Growth and cellulose synthesis inhibition by P4B were greatly reduced in a novel mutant for the cellulose synthase catalytic subunit gene CESA3 (cesa3pbr1). Cross-tolerance to P4B was also observed for isoxaben-resistant (ixr) cesa3 mutants ixr1-1 and ixr1-2. P4B has an original mode of action as compared with most other CBIs. Indeed, short-term treatments with P4B did not affect the velocity of cellulose synthase complexes (CSCs) but led to a decrease in CSC density in the plasma membrane without affecting their accumulation in microtubule-associated compartments. This was observed in the wild type but not in a cesa3pbr1 background. This reduced density correlated with a reduced delivery rate of CSCs to the plasma membrane but also with changes in cortical microtubule dynamics and orientation. At longer timescales, however, the responses to P4B treatments resembled those to other CBIs, including the inhibition of CSC motility, reduced growth anisotropy, interference with the assembly of an extensible wall, pectin demethylesterification, and ectopic lignin and callose accumulation. Together, the data suggest that P4B either directly targets CESA3 or affects another cellular function related to CSC plasma membrane delivery and/or microtubule dynamics that is bypassed specifically by mutations in CESA3.
Aim: DNA methylation is a promising diagnostic biomarker for various cancers including hepatocellular carcinoma (HCC). We aimed to identify aberrant DNA methylation and protein alterations via integrated approaches and develop a highly predictive biomarker panel for blood‐based discrimination of HCC from non‐HCC chronic liver disease (CLD) in an HBV‐predominant population. Methods: Genome‐wide methylation profiling was conducted to screen hypermethylated CpG sites and genes distinguishing 55 HCC and matched non‐HCC tissues. Candidate marker genes were then evaluated with five protein markers in 299 blood samples, and a diagnostic model was developed and validated in an independent cohort of 149 participants. Results: Methylation pattern analysis identified 44 candidate hypermethylation biomarkers using four strategies. Through cross‐validation, a panel of six methylation markers from four different groups yielded an AUC of 0.938, surpassing other methylation marker panels. A logistic regression model incorporating four DNA methylation markers and two protein markers achieved sensitivities of 91.8% and 88.4% at specificities of 95.4% and 93.8% in the training and validation sets, respectively. The 6‐marker panel showed higher sensitivity of 82.9% for BCLC 0‐A HCC, outperforming alpha‐fetoprotein (AFP), and des‐gamma‐carboxyprothrombin (DCP). Conclusions: The developed 6‐marker model demonstrated strong diagnostic performance for distinguishing HCC from non‐HCC CLD in the studied HBV‐predominant cohorts. It outperformed AFP and DCP in this case–control setting and may have potential for blood‐based HCC detection. Prospective validation in surveillance cohorts is required before clinical implementation.